Ocean Biomedical, Inc. financial data

Symbol
OCEA, OCEAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
515 Madison Ave Suite 8078, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Ocean Biomedical, Inc./DE (to 2/15/2023), Aesther Healthcare Acquisition Corp. (to 2/14/2023)
Latest financial report
10-K - Q4 2023 - Nov 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.9 % -82.8%
Debt-to-equity -103 % -56.7%
Return On Equity 162 % -12%
Return On Assets -5.09K % -23925%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.8M shares
Common Stock, Shares, Outstanding 34.6M shares +48.4%
Entity Public Float 1 USD -100%
Weighted Average Number of Shares Outstanding, Basic 26.3M shares +12.6%
Weighted Average Number of Shares Outstanding, Diluted 26.3M shares +12.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 709K USD -91.6%
General and Administrative Expense 9.51M USD +23.2%
Operating Income (Loss) -10.2M USD +36.6%
Nonoperating Income (Expense) -104M USD -8321%
Net Income (Loss) Attributable to Parent -114M USD -559%
Earnings Per Share, Basic -4.35 USD/shares -488%
Earnings Per Share, Diluted -4.35 USD/shares -488%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD
Assets, Current 2.11M USD +14.5%
Assets 5.5M USD +199%
Accounts Payable, Current 16.2M USD +41.5%
Accrued Liabilities, Current 946K USD +113%
Liabilities, Current 30M USD +137%
Liabilities 96.3M USD +660%
Retained Earnings (Accumulated Deficit) -196M USD -140%
Stockholders' Equity Attributable to Parent -90.8M USD -739%
Liabilities and Equity 5.5M USD +199%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.65M USD -622%
Net Cash Provided by (Used in) Financing Activities 2.92M USD +388%
Common Stock, Shares Authorized 300M shares +66.1%
Common Stock, Shares, Issued 34.6M shares +48.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 272K USD +17.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1M USD
Deferred Tax Assets, Valuation Allowance 20.8M USD +29.1%
Deferred Tax Assets, Gross 20.8M USD +29.1%
Deferred Tax Assets, Operating Loss Carryforwards 5.96M USD +346%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +700%
Additional Paid in Capital 105M USD +48.8%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 186K USD -93.7%
Interest Expense 50K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%